Jean-Christophe Boyer

Author

Centre Hospitalier Universitaire de Nîmes

Also Known As

Boyer, Jean-Christophe, Jean-Christophe Boyer

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

Centre Hospitalier Universitaire de Nîmes Inserm Université de Montpellier Université de Bordeaux Hôpital de la Timone

About

Jean-Christophe Boyer is an author at Centre Hospitalier Universitaire de Nîmes specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	222
2	Pathology	4	4	199
3	Health Sciences	1	1	23
4	Natural Sciences	1	1	20
5	Molecular Biology	1	1	20

Jean-Christophe Boyer

Publications

663

Citations

H-Index

Page 1

	Year	Citations
A Comparison of the Pharmacodynamics and Pharmacokinetics of Bupivacaine, Ropivacaine (with Epinephrine) and Their Equal Volume Mixtures with Lidocaine Used for Femoral and Sciatic Nerve Blocks: A Double-Blind Randomized Study Philippe Cuvillon, Emmanuel Nouvellon, Jacques Ripart, Anesthesia & Analgesia	2009	167
Antiphospholipid/antiprotein antibodies, hemostasis-related autoantibodies, and plasma homocysteine as risk factors for a first early pregnancy loss: a matched case-control study Jean‐Christophe Gris, Thomas Perneger, I. Quéré, Blood	2003	93
A Rapid and Inexpensive Method for Anticipating Severe Toxicity to Fluorouracil and Fluorouracil-based Chemotherapy Joseph Ciccolini, Cédric Mercier, Alexandre Evrard, Therapeutic Drug Monitoring Oral CapecitabineCancer ManagementCapecitabine IntakePathologyPharmacotherapy	2006	83
Factors for Hematopoietic Toxicity of Carboplatin: Refining the Targeting of Carboplatin Systemic Exposure Antonin Schmitt, Laurence Gladieff, Céline M. Laffont, Journal of Clinical Oncology	2010	55
Cross-Validation Study for Epidermal Growth Factor Receptor and KRAS Mutation Detection in 74 Blinded Non-small Cell Lung Carcinoma Samples: A Total of 5550 Exons Sequenced by 15 Molecular French Laboratories (Evaluation of the EGFR Mutation Status for the Administration of EGFR-TKIs in Non-Small Cell Lung Carcinoma [ERMETIC] Project—Part 1) Michèle Beau‐Faller, Armelle Degeorges, Estelle Rolland, Journal of Thoracic Oncology Cross-validation StudyKras Mutation DetectionCancer DetectionMedicinePathology	2011	54
Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency Joseph Ciccolini, Cédric Mercier, Laëtitia Dahan, Cancer Chemotherapy and Pharmacology Dihydropyrimidine Deshydrogenase DeficiencyMedicinePathologyPoisoningProbable Implication	2005	42
Reversal of Bupivacaine-Induced Cardiac Electrophysiologic Changes by Two Lipid Emulsions in Anesthetized and Mechanically Ventilated Piglets Damien Candela, Guillaume Louart, Philippe‐Jean Bousquet, Anesthesia & Analgesia	2010	37
Management of Maternal Amanita phalloıdes Poisoning during the First Trimester of Pregnancy: A Case Report and Review of the Literature Jean-Christophe Boyer, F.J.Cortejoso Hernández, J Estorc, Clinical Chemistry	2001	35
Performance and Cost Efficiency of KRAS Mutation Testing for Metastatic Colorectal Cancer in Routine Diagnosis: The MOKAECM Study, a Nationwide Experience Hélène Blons, Étienne Rouleau, Nathanaël Charrier, PLoS ONE	2013	23
Effect of Single Nucleotide Polymorphisms in the Xenobiotic-sensing Receptors NR1I2 and NR1I3 on the Pharmacokinetics and Toxicity of Irinotecan in Colorectal Cancer Patients Litaty Mbatchi, Jacques Robert, Marc Ychou, Clinical Pharmacokinetics Health SciencesSingle Nucleotide PolymorphismsMedicineOncogenic AgentPharmacology	2016	23

Page 1